BofA raises target for ConvaTec stock to GBp 300

Published on 10/01/2026 at 09:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Nine brokers give ConvaTec a Moderate Buy consensus. ConvaTec stock costs EUR 2.49 on October 1, 2026 after EUR 2.55, down 2.35 percent.

Moderne Medizintechnik-Reinraumfertigung mit Technikern an steriler Produktionslinie — ConvaTec Group Plc GB00BD3VFW73 zeigt moderne Medizintechnik-Fertigung mit sterilen Produktionslinien und Reinraumtechnikern, Illustration mit AI erstellt.

ConvaTec (ISIN GB00BD3VFW73) was trading at EUR 2.49 at Lang & Schwarz on October 1, 2026 at 9:31 a.m. CEST, down 2.35 percent versus the EUR 2.55 prior close. BofA raised its target from GBp 295.00 to GBp 300.00 and kept a buy rating on September 29, 2026, as reported by Morningstar.

BofA target moves to GBp 300

The latest target action gives ConvaTec a modest increase of GBp 5.00, or 1.69 percent, from BofA's previous GBp 295.00 level. The recommendation remained buy, while the target stays below the broader broker average of GBp 305.44.

MarketBeat reported on September 28, 2026 that nine brokers rated the stock with a Moderate Buy consensus: eight buy ratings and one hold. The average 12-month target was GBp 305.44, with published targets spanning GBp 270.00 to GBp 335.00.

Buyback reaches 5,226,866 shares

Capital allocation is the second concrete support in the current setup. On September 28, 2026, Investegate published the company announcement that ConvaTec bought 5,226,866 ordinary shares between September 21 and September 25 as part of its USD 200 million buyback program.

The purchases were made at volume-weighted average prices from GBp 210.33 to GBp 215.59 and were placed into treasury. After the transactions, treasury holdings reached 132,464,819 shares, while 1,917,324,740 ordinary shares remained in issue for voting-rights calculations.

London listing and euro quote

ConvaTec develops medical products and technologies for chronic-condition management, including wound care and ostomy products. Its primary listing is on the London Stock Exchange under ticker CTEC.L, with the shares quoted in GBp; the company is classified in Health Care by Global Banking and Finance.

MarketBeat placed the London-listed company at a market capitalization of GBP 4.1 billion on September 28, 2026. That valuation and the GBp 305.44 average target provide a separate comparison to the euro-denominated Lang & Schwarz quote.

The euro quote falls below EUR 2.55

ConvaTec was trading at EUR 2.49 at Lang & Schwarz on October 1, 2026 at 9:31 a.m. CEST, down 2.35 percent versus the EUR 2.55 prior close. The further course of trading is shown by the continuously updated real-time quote of ConvaTec stock.